INTRALIPID is a brand name for Soybean Oil, supplied as a emulsion. The medicine, its uses, side effects and dosage are the same regardless of brand.
Verbatim from this product's HC label. Tap a section to expand.
INTRALIPID infusion may cause a rise in body temperature and, less frequently, shivering, chills, nausea, vomiting, headache, back or chest pain with dyspnea and cyanosis (incidence <1%). Table 1 Frequency of Adverse Drug Reactions SOC According to WHO Frequency Symptom Body as a whole - general disorders Uncommon (>1/1 000, <1/100 Very rare (<1/10 000) Headache, Rise in body temperature, Shivering, Chills, Tiredness Anaphylactic reaction Cardiovascular disorder Very rare (<1/10 000) Circulatory effects (hyper/hypotension) Gastrointestinal disorders Uncommon (>1/1 000 <1/100) Abdominal pain, Nausea, Vomiting Liver & biliary system disorder Very rare (<1/10 000) Transient increase in liver function test Musculoskeletal, connective tissue and bone disorders Very rare (<1/10 000) Abnormal pain Platelet, bleeding & clotting disorders Very rare (<1/10 000) Thrombocytopenia Red blood cell disorders Very rare (<1/10 000) Haemolysis, Reticulocytosis Reproductive disorders, male Very rare (<1/10 000) Priapism Skin and appendages disorders Very rare (<1/10 000) Rash, Urticaria 9 Thrombocytopenia has been reported in association with prolonged treatment with INTRALIPID in infants.
Transient increases in liver function tests after prolonged intravenous nutrition with or without INTRALIPID have also been noted. Increased cholesterol has been observed with infants after long term treatment with Intralipid 10%. The reasons are not clear at present.
Fat overload syndrome:
An impaired capacity to eliminate INTRALIPID may lead to the fat overload syndrome as a result of overdosage. However, this syndrome may appear also at recommended rates of infusion in association with a sudden change in the patient’s clinical condition, such as renal function impairment or infection.
The fat overload syndrome is characterised by hyperlipemia, fever, fat infiltration and disorders in various organs and coma. All symptoms are usually reversible if the infusion of INTRALIPID is discontinued. SYMPTOMS AND TREATMENT OF OVERDOSAGE See Adverse Reactions “Fat overload syndrome”.
Severe overdose of fat emulsions containing triglycerides can, especially if carbohydrates are not administered simultaneously, lead to acidosis. When fat emulsion is given in amounts exceeding the capacity of fat elimination the following symptoms may occur: hyperlipemia, hepatosplenomegaly, jaundice, hemolytic anemia, prolonged clotting time and thrombocytopenia.
All symptoms clear in days to weeks after cessation of fat infusion. For further information on the management of suspected drug overdose, contact your regional Poison Control Centre. 7 mL per kg of INTRALIPID 10%, 20% and 30%, respectively).
In raised energy requirements, the supply of INTRALIPID can be increased but should not, without special precautions, exceed a quantity corresponding to 3 g fat (30 mL, 15 mL and 10 mL of Intralipid 10%, 20% and 30% respectively) per kg body weight/day.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Soybean Oil in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
For prevention of essential fatty acid deficiency:
The recommended minimum requirement is approximately 4% of the caloric intake. In most patients, this can be supplied as 500 mL of INTRALIPID 10% administered intravenously twice weekly. The drip rate is adjusted to about 2–3 mL per minute for INTRALIPID 10% and about 1-2 mL per minute of INTRALIPID 20% at which rates 500 mL can be infused in 3–5 hours and 5–9 hours, respectively.
The infusion time for 500 mL must not be shorter than 3 and 5 hours, respectively. The infusion should be started at half the infusion rate during the first 30 minutes, under supervision. A daily supplement of 333 mL of INTRALIPID 30% (100 g fat) is regarded as sufficient to meet the basal metabolic requirements of a 70 kg patient on total parenteral nutrition.
6-1 mL per minute at which rate 333 mL can be infused over a period of 5- 10 hours. The rate of infusion should not exceed 333 mL of INTRALIPID 30% over a 5 hour period. The infusion should be started at half the infusion rate during the first 30 minutes, under supervision.
Pediatrics The infant's ability to eliminate fat should govern the dosage (see CONTRA-INDICATIONS and PRECAUTIONS). 5-20 mL INTRALIPID 20% and 5-40 mL INTRALIPID 10% per kg body 11 weight, respectively. 5 g fat per kg bodyweight per 24 hours.
The dose should be increased in relation to the infant's ability to eliminate fat, which should be checked daily (see Fat elimination test). The daily dose should preferably be administered continuously over 24 hours by infusion pump.
Due to the lack of experience, INTRALIPID 30% is not recommended for use in infants. Administration Light exposure of parenteral nutrition, especially after admixture with trace elements and/or vitamins, may have adverse effects on clinical outcome in neonates, due to generation of peroxides and other degradation products.
When used in neonates and children below 2 years, INTRALIPID (in bags and administration sets) should be protected from ambient light until administration is completed. See SPECIAL HANDLING INSTRUCTIONS. STORAGE AND STABILITY Shelf life of the medicinal product as packaged for sale: 24 months.
For use once the overwrap is removed. Store up to 25°C. Do not freeze. Do not use INTRALIPID after the expiry date printed on the container. When used in neonates and children below 2 years, INTRALIPID (in bags and administration sets) should be protected from light exposure until administration is completed 12 Shelf life after first opening the container The emulsion should be used directly due to the risk of microbiological contamination.
From a microbiological point of view the emulsion should be used immediately after […]